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ARTICLE
Chemical modification of proteins by insertion
of synthetic peptides using tandem protein
trans-splicing
K. K. Khoo 1,3, I. Galleano1,3, F. Gasparri 1, R. Wieneke 2, H. Harms1, M. H. Poulsen1, H. C. Chua 1,
M. Wulf1, R. Tampé 2 & S. A. Pless 1✉
Manipulation of proteins by chemical modification is a powerful way to decipher their
function. However, most ribosome-dependent and semi-synthetic methods have limitations
in the number and type of modifications that can be introduced, especially in live cells. Here,
we present an approach to incorporate single or multiple post-translational modifications or
non-canonical amino acids into proteins expressed in eukaryotic cells. We insert synthetic
peptides into GFP, NaV1.5 and P2X2 receptors via tandem protein trans-splicing using two
orthogonal split intein pairs and validate our approach by investigating protein function. We
anticipate the approach will overcome some drawbacks of existing protein enigineering
methods.
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Chemical or genetic engineering of proteins provides greatpotential to study protein function and pharmacology orto generate proteins with novel properties. However,
despite recent technical achievements1,2, the type of chemical
modification that can be accomplished by genetic means (e.g.,
amber codon suppression) is limited to incorporation of non-
canonical amino acids (ncAAs) due to the tolerance of the cell’s
translational machinery. Additionally, insertion of multiple che-
mical modifications by genetic code expansion remains a chal-
lenge, particularly in eukaryotic cells. Semi-synthetic approaches
offer an alternative means to manipulate proteins post-transla-
tionally, but these modifications have typically been performed
in vitro3–8. We thus sought to complement these approaches with
a method that could incorporate synthetic peptides carrying
multiple post-translational modifications (PTMs) or ncAAs into
both cytosolic and membrane proteins in live eukaryotic cells.
Split intein pairs comprise complementary N- and C-terminal
intein fragments (IntN and IntC) that assemble with extraordinary
specificity and affinity to form an active intein. This assembly
results in a spontaneous, essentially traceless splicing reaction that
covalently links the two flanking protein segments through native
chemical ligation9. The critical requirement for splicing to occur
is typically the presence of a Cys, Ser, or Thr side chain
(depending on the split intein in question) in the +1 position of
the extein (the sequence flanking the split intein), and multiple
split inteins have recently been optimized for increased splicing
efficiency10–12. The latter facilitates the simultaneous use of two
orthogonal split inteins within the same peptide or protein, an
approach termed tandem protein trans-splicing (tPTS). However,
tPTS has largely been conducted in vitro or restricted to bacterial
expression systems, cell lysates, nuclear extracts, or selection
protocols8,13–15. Indeed, most live-cell applications of PTS utilize
single split inteins for the purpose of N/C-terminal tagging16–18
or manipulating protein assembly/expression19,20.
Here, we employ tPTS using two orthogonal split-intein pairs
to insert synthetic peptides into proteins between two splice sites
(A and B). This approach permits the introduction of a virtually
limitless array of modifications, including PTMs, PTM mimics,
and ncAAs, into live eukaryotic cells and allows multiple mod-
ifications to be made simultaneously (Fig. 1). We validate our
approach by using tPTS to modify GFP, intracellular regions of
the NaV1.5 channel, and the extracellular domain of the P2X2
receptor, allowing us to gain insight into the role of PTMs and
PTM mimics in ion channel function and the importance of
spatial positioning of charge in ligand sensitivity.
Results
Post-translational incorporation of synthetic peptides. Our goal
was to generate semi-synthetic proteins in live eukaryotic cells by
post-translationally incorporating ncAAs or PTMs into a protein
of interest. We achieved this by using two orthogonal split inteins
(A and B) to insert a synthetic peptide carrying these modifica-
tions. We designed three fragments of the protein of interest
(Fig. 1), corresponding to N and C-terminal fragments (N and C),
and a shorter central fragment containing the desired modifica-
tion (peptide X). Fragments N and C were heterologously
expressed in the cell, while peptide X was generated synthetically
and inserted into the cell via an appropriate technique (e.g.,
injection). To covalently assemble the three fragments, the highly
efficient engineered derivative of the NpuDnaE split intein
(termed CfaDnaE)11 was employed as split intein A. The first 101
amino acids of its N-terminus (IntN-A) were expressed as a
fusion construct at the C-terminus of protein fragment N. The
corresponding C-terminal part (IntC-A), consisting of amino
acids 102–137, were attached to the N-terminal end of peptide X.
The optimized split-intein SspDnaBM86 (ref. 10) was chosen as
split intein B because it can be split highly asymmetrically and has
previously been shown to be orthogonal to the NpuDnaE split
intein21. Its N-terminal part (IntN-B), comprising only the first 11
amino acids, was added to the C-terminus of peptide X. The
corresponding C-terminal part (IntC-B), consisting of amino
acids 12-154, was expressed as a fusion construct at the N-
terminus of protein fragment C (Fig. 1).
Replacing Nav1.5 interdomain linkers with synthetic peptides.
To demonstrate the feasibility of our approach, we chose the well-
characterized cardiac voltage-gated sodium channel isoform
NaV1.5, which is crucial for the initiation and propagation of the
cardiac action potential22. This large 2016-amino acid protein
comprises four homologous domains (DI-DIV) that are con-
nected by intracellular linkers (Fig. 2a). Dysfunction of NaV1.5
can arise from mutations, as well as dysregulated PTMs. For
example, acetylation of K1479 and changes in phosphorylation of
the linker between DIII–DIV have been shown to play a role in
cardiac disease23,24. However, interrogation of the role of PTMs
has been hampered by the inability to express a homogenous
population of channels containing a defined number of PTMs in
living cells. Thus, although phosphorylation at Y1495 is known to
affect channel function25 and phosphorylation can be prevented
in a channel population by mutating Y1495 to phenylalanine, this
population cannot be compared with one that is fully modified
because the extent of phosphorylation cannot be controlled.
Similarly, it is not known if there are synergistic effects with other
PTMs in the vicinity, e.g., acetylation of K1479.
We tested the tPTS strategy by reconstituting full-length
NaV1.5 from three recombinantly co-expressed channel frag-
ments. To this end, we designed three different gene constructs:
(1) an N-terminal construct (N) comprising amino acids 1–1471
of Nav1.5 (equivalent to DI-III) fused to the N-terminal part of
CfaDnaE (IntN-A); (2) a C-terminal construct (C) corresponding
to the C-terminal part of SspDnaBM86 (IntC-B) linked to the C-
N-fragment C-fragment
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Fig. 1 Schematic diagram of the tPTS strategy to incorporate
recombinant and synthetic proteins. The chosen split inteins used in this
study, inteins A (CfaDnaE) and B (SspDnaBM86), are indicated by square
and round symbols, respectively. Flanking +1, +2, +3 extein residues for
each intein are indicated in italics at their respective positions in the top
panel. The +1 extein residue (underlined) is a critical requirement for
splicing to occur. X denotes that the type of residue at that position is not
critical for splicing, although they might affect the kinetics or splicing
efficiency.
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terminal amino acids 1503–2016 of Nav1.5 (equivalent to DIV);
and (3) a peptide X fragment (termed XNav1.5REC) corresponding
to the sequence to be replaced in the DIII–DIV linker of NaV1.5
(amino acids 1472 to 1502 of NaV1.5 but with N1472 mutated to
Cys to enable splicing) flanked N- and C-terminally by IntC of
CfaDnaE (IntC-A) and IntN of SspDnaBM86 (IntN-B), respectively
(Fig. 2a). These constructs were transcribed into messenger RNA
(mRNA) and injected into Xenopus laevis oocytes for recombi-
nant expression. This approach is well-established for assessing
ion channel function using electrophysiology and, conveniently,
allows for direct delivery of mRNA and/or peptides into the
cytosol using microinjection26.
As the peptide X fragment contained the N1472C mutation, we
first compared the function of WT channels with N1472C mutant
channels and the spliced product resulting from co-injection of
N+ C+ XNav1.5REC (Fig. 2b). As expected, injection of full-length
WT and N1472C mRNA constructs resulted in robust channel
expression, although the steady-state inactivation profile of
N1472C was shifted slightly to more depolarized potentials,
consistent with earlier reports, suggesting for the N1472 locus to
be potentially involved in cardiac disease27 (Fig. 2b–e and
Supplementary Table 1). Remarkably, co-injection of mRNA
corresponding to N+ C+ XNav1.5REC (i.e., containing the
N1472C mutation) resulted in full-length channels that showed
robust current levels and were functionally indistinguishable from
the full-length, recombinantly expressed channel construct also
bearing the N1472C mutation (Fig. 2d, e). Importantly, co-
expression of only two of the three constructs (i.e., N+C, N+
XNav1.5REC, or C+ XNav1.5REC) did not result in any voltage-
dependent sodium current (Fig. 2b). Immunoblot analysis of co-
expressed proteins also verified the presence of fully spliced
Nav1.5 when XNav1.5REC was co-expressed with both N and C
constructs, although the relative abundance of fully spliced
product was low compared to unspliced or splicing side products
(<2% estimated based on immunoblots of total cell lysates;
Fig. 2c). Importantly, a band corresponding to fully spliced
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Fig. 2 Insertion of recombinantly expressed peptides into the DIII–IV linker of NaV1.5. a Schematic presentation of the strategy to reconstruct full-length
NaV1.5 from recombinantly expressed N-/C-terminal fragments (N and C) and a recombinantly expressed peptide corresponding to amino acids 1472 to
1502 of the NaV1.5 DIII–DIV linker (X) in Xenopus laevis oocytes. Inteins A (CfaDnaE) and B (SspDnaBM86) are indicated by square and round symbols,
respectively. Note that we cannot exclude the possibility that splicing takes place at a different subcellular location than depicted here. b Representative
sodium currents in response to sodium channel activation protocol (see methods; only voltage steps from −50 to +10 mV in 10mV steps are displayed),
demonstrating expression of functional NaV1.5 only in the presence of all three components (N+ C+ X), along with WT and N1472C channels (the latter
mutation was introduced to create an optimized splice site for intein A. c Immunoblots verifying the presence of fully spliced NaV1.5 only when all three
components (N+ C+ X) were co-expressed (using antibody against NaV1.5 C-terminus). NaV1.5 band was not detected when one component was
missing (left blot) or when non-splicing mutation (N+ C+ X mut.) was introduced to prevent splicing (right blot; see Supplementary Fig. 2). Black arrows
indicate band positions of the respective constructs (Actual MW of constructs: WT, 227 kDa; C-construct, 79 kDa; C+ X, 65 kDa; C-terminal cleavage
product, C*, 58 kDa). Note that X and XREC refer to XNav1.5REC in this panel. d Steady-state inactivation and conductance–voltage (G–V) relationships for
functional constructs tested. e Comparison of values for half-maximal (in)activation (V50) (values are displayed as mean+ /– SD; WT, n= 12; N1472C,
n= 14; N+ C+ XNav1.5REC, n= 16). Significant differences were determined by one-way ANOVA with a Tukey post-hoc test. *p < 0.03 (WT vs. N1472C,
p= 0.014; WT vs. N+ C+ XNav1.5REC, p= 0.012). Source data are provided as a Source data file.
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product was not detected when a splicing-incompetent mutation
(+1 extein Ser to Ala mutation in the C construct at splice site B)
was introduced (N+ C+ XNav1.5REC(mut.) in Fig. 2c). Indeed,
non-covalent assembly arising from split intein cleavage products
and/or partially spliced channel fragments did not occur within
the typical timeframe of our experiments (Supplementary Fig. 1).
Altogether, these data demonstrate that tPTS can be used to
assemble full-length Nav1.5 in live cells.
Having established that recombinant expression of N+C+
XNav1.5REC can yield functional Nav1.5 channels, we next
generated synthetic versions of peptide X (XNav1.5SYN; see
Supplementary Fig. 2 for synthesis strategy) for injection into
cells expressing only the N and C fragments recombinantly
(Fig. 3a). Specifically, we synthesized XNav1.5SYN constructs that
contained one of the following four variants: (i) mutations
K1479R and Y1495F (termed [NM]Syn) to prevent acetylation
and phosphorylation, respectively; (ii) a thio-acetylated Lys
analog at position 1479 (tAcK1479) that mimics PTM but
displays increased metabolic stability against sirtuins compared to
regular acetylation28,29; (iii) a phosphonylated Tyr analog at
position 1495 (phY1495) that provides a non-hydrolysable
phosphate mimic; or (iv) both tAcK1479 and phY1495 to mimic
a dual PTM scenario (Fig. 3b). The N and C fragments were
recombinantly expressed in oocytes for 24 h before injection of
the synthetic XNav1.5SYN variants. Successful splicing of full-length
Nav1.5 containing one of the four synthetic XNav1.5SYN variants
was verified by immunoblotting and electrophysiology (Fig. 3c,
d). As before, the relative abundance of fully spliced product
estimated from immunoblot analysis was low compared to the
abundance of unspliced or splicing side products (<1% in total
cell lysates), but expression of robust voltage-gated sodium
currents was achieved within 12 h of XNav1.5SYN variant injection.
In fact, observed current levels at 24 h post peptide injection (i.e.,
48 h after injection of N- and C-mRNA) were comparable to
those observed 48 h after injection of WT mRNA (Fig. 3e and
Supplementary Fig. 3). To the best of our knowledge, this
represents the first incorporation of a tAcK residue and the first
insertion of two distinct PTM mimics in a full-length protein in
eukaryotic cells. Functional analysis demonstrated that the
voltage dependence of activation was not affected by any of the
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Fig. 3 Insertion of synthetic peptides into NaV1.5. a Schematic of strategy to reconstruct full-length NaV1.5 from recombinantly expressed N-/C-terminal
fragments (N and C) and a synthetic peptide (XNav1.5SYN) in Xenopus laevis oocytes. Inteins A (CfaDnaE) and B (SspDnaBM86) indicated by square and
round symbols, respectively. Note: we cannot exclude that splicing takes place at a different subcellular location than depicted. b Peptide XNav1.5SYN
sequence corresponding to amino acids replaced in the NaV1.5 DIII–DIV linker and chemical structures of native amino acids and PTM mimics (tAcK/phY)
incorporated via chemical synthesis of peptide XNav1.5SYN. The N1472C (underlined) mutation was introduced to optimize splicing (Supplementary Fig. 1).
c Immunoblot verifying the presence of fully spliced NaV1.5 only when peptide XNav1.5SYN was co-injected with N and C. Black arrows indicate band
positions of the respective constructs (Actual MW of constructs: WT, 227 kDa; C, 79 kDa; C+ X, 65 kDa; C-terminal cleavage product, C*, 58 kDa). Band
at ~150 kDa is possibly a dimer or aggregate of C. d Representative sodium currents (see Methods; only voltage steps from −50 to +10 mV in 10mV steps
are displayed), demonstrating expression of functional NaV1.5 when Xenopus laevis oocytes expressing N and C constructs were injected with synthetic
peptides containing non-modifiable side chains in positions 1479 and 1495 (K1479R and Y1495F, NM), tAcK1479 or phY1495 or both PTM mimics
together. e Average current amplitudes recorded at −35mV from oocytes expressing N and C constructs and injected with synthetic peptide variant NM
or phY1495 depicted as a bar plot (mean+ /– SD; WT, n= 8; NM, n= 9; phY, n= 8; N+ C, n= 6). Currents normalized to mean currents measured from
oocytes expressing the full-length WT construct. To ensure adequate control of voltage clamp, [Na+] in the extracellular recording solution was reduced
(see Supplementary Fig. 3 for details). f Steady-state inactivation and conductance–voltage (G–V) relationships for PTM-modified/non-modified
constructs (values displayed as mean+ /– SD; N1472C, n= 15; NM, n= 10; tAcK1479, n= 21; phY1495, n= 19; tAcK1479+ phY1495, n= 14). Source data
are provided as a Source data file.
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introduced PTM mimics or the conventional K1479R and
Y1495F mutations. Conversely, insertion of phY1495, either
alone or in combination with tAcK1479, induced a clearly
discernable (15 mV) rightward-shift in the voltage-dependence of
fast inactivation (Fig. 3f and Supplementary Table 1). These data
are consistent with earlier reports, suggesting that acetylation of
K1479 primarily affects current density24, whereas phosphoryla-
tion of Y1495 affects fast inactivation properties25.
To further validate our approach and demonstrate its
suitability for other target sequences, we applied the same
strategy to the intracellular linker connecting DI and II of NaV1.5.
Similar to the DIII–IV linker, mutations or aberrant PTMs in this
region of NaV1.5 have been implicated in cardiac disease23,30.
Using appropriate N and C constructs, together with both
recombinantly expressed and synthetic versions of a peptide
XNav1.5 variant corresponding to amino acids 505 to 527 of
NaV1.5, we demonstrated that tPTS can be used to probe the
function of different intracellular regions of NaV1.5 in Xenopus
oocytes. Specifically, we found that neither methylation of R513
(meR513), nor phosphonylation of S516 (phS516), nor their
combined presence31, affected activation or inactivation of
NaV1.5 (Supplementary Figs. 4 and 5 and Supplementary
Table 1).
Semi-synthesis of GFP in HEK cells. The above data showed that
tPTS could be used to insert synthetic peptides into large mem-
brane proteins in live eukaryotic cells, but it was important to
demonstrate delivery into mammalian cells, which can be more
challenging. To demonstrate the feasibility of this approach in
mammalian cells, we split GFP into three fragments (analogous to
our approach with Nav1.5 described above): (1) an N-terminal
construct (N-GFP) corresponding to amino acids 1–64 of GFP,
fused to IntN of CfaDnaE; (2) a C-terminal construct (C-GFP)
corresponding to IntC of SspDnaBM86 linked to amino acids
86–238 of GFP, and (3) a peptide X fragment (XGFPREC) corre-
sponding to amino acids 65 to 85 and flanked by IntC of CfaDnaE
at the N-terminus and by IntN of SspDnaBM86 at the C-terminus
(Fig. 4a). The constructs were co-expressed in different combi-
nations in human embryonic kidney (HEK) cells, which expres-
sed functional GFP only when all three constructs (N-GFP+ C-
GFP+ XGFPREC) were transfected, albeit with low yields (~4%, as
estimated by fluorescence-activated cell sorting (FACS), Supple-
mentary Fig. 6). No GFP fluorescence was detected with the co-
expression of any two constructs or when cells were transfected
with constructs containing splicing-incompetent mutations
(C65A at +1 extein XGFPREC (splice site A) or S85A at +1 extein
C-GFP (splice site B); Fig. 4b).
We subsequently sought to generate a semi-synthetic GFP by
delivering synthetic peptide XGFPSYN variants into HEK cells that
recombinantly expressed N- and C-terminal fragments of GFP
(Fig. 5a). We achieved delivery of synthetic peptides using the
transient cell permeabilization method known as cell squeezing,
which involves rapid viscoelastic deformation32. Although yields
were low (~1%), GFP fluorescence was detected only in N-GFP-
and C-GFP-transfected cells that had been squeezed in the
presence of peptide XGFPSYN (Fig. 5b). The approach further
allowed us to incorporate the ncAA 3-nitro-tyrosine at position
66 of GFP to replace the tyrosine that is involved in chromophore
formation. This modification resulted in a blue-shift in the
spectral properties of GFP and confirmed the utility of tPTS for
creating semi-synthetic variants in mammalian cells (Supple-
mentary Fig. 7).
Insertion of ncAAs into P2X2 receptor extracellular domain.
While standard PTS has been employed to splice numerous
cytosolic proteins and peptides, extracellular targets are more
challenging and have been rarely investigated using PTS17. We
sought to test whether tPTS could be used to insert synthetic
peptides into an extracellular protein domain. We chose the P2X2
receptor (P2X2R), a trimeric ATP-gated ion channel whose
extracellular domain binds ATP released during synaptic trans-
mission33. While the location of the ATP-binding site in the
extracellular domain is undisputed, the details of how conserved
basic side chains coordinate the phosphate tail of ATP remain
unclear34. However, ribosome-based non-sense suppression
approaches, using, e.g., ncAA analogs of lysine, have failed at
position K71 in the P2X2R, likely due to non-specific incor-
poration of endogenous amino acids (Supplementary Fig. 8). We,
therefore, used tPTS to test whether the charge position of K71 is
crucial for ATP recognition.
As an initial proof-of-concept of splicing within an extra-
cellular domain of a membrane receptor, we used standard PTS to
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Fig. 4 Insertion of a recombinantly expressed peptide into GFP expressed
in mammalian cells. a Schematic presentation of the strategy applied to
reconstitute GFP from recombinantly expressed N-/C-terminal fragments
and recombinantly expressed peptide XGFPREC corresponding to amino
acids 65–85 of GFP in HEK293 cells. Inteins A (CfaDnaE) and B
(SspDnaBM86) are indicated by square and round symbols, respectively.
b Bright-field (right panels) and fluorescence (left panels) images of
HEK293 cells expressing the indicated constructs. Scale bars: 20 µm. GFP
fluorescence was only detected when all three constructs (N+ X+ C) were
co-transfected. GFP fluorescence was not detected when one of the three
constructs was absent or when +1 extein residues of each split intein is
mutated to alanine (C65A for intein A and S86A for intein B) to prevent
splicing.
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independently assess splicing at either side of K71 in P2X2R: S54,
which was mutated to Cys to improve splicing (splice site A), and
S76 (splice site B). Again, we chose Xenopus leavis oocytes as an
expression system, as they allow facile peptide delivery. For splice
site A, the N-terminal fragment contained amino acids 1-53 of
P2X2 linked to IntN of CfaDnaE. However, the C-terminal
construct contained a faux transmembrane domain (amino acids
1–74 from ASIC1a) followed by IntC of CfaDnaE and the C-
terminal receptor fragment of P2X2 (amino acids 54–472)
(Supplementary Fig. 9a). Introduction of the faux transmembrane
segment was necessary to enforce the correct topology of the
resulting construct. To demonstrate that successful splicing is
necessary for assembly of full-length receptors, we also generated
a version of the C-terminal construct containing the C54A
mutation, which effectively removes the required +1 Cys side
chain and renders the construct splicing incompetent (Supple-
mentary Fig. 9b). Expression of the individual constructs alone (N
or C) in Xenopus oocytes did not result in functional receptors,
whereas co-expression of N+C (but not N+C (C54A)) resulted
in receptors with WT-like ATP sensitivity (Supplementary Fig. 9c,
d). Confirmation of correct splicing was provided by immuno-
blots showing that bands corresponding to WT P2X2 only
occurred in the presence of N+ C, but not any of the control
constructs (Supplementary Fig. 9e). Of note, biochemical analysis
confirmed that splicing was highly efficient, with near complete
conversion of the N and C fragments to full-length receptors.
We proceeded to test splice site B, employing an analogous
approach to that implemented for splice site A (Supplementary
Fig. 10a, b), except we used the SspDnaBM86 split intein in this
case together with amino acids 1–75 of P2X2 (N-terminal
fragment) and amino acids 76–472 of P2X2 plus a faux
transmembrane segment (C-terminal fragment). Similar to the
results obtained at splice site A, full-length P2X2 receptors with
WT-like ATP sensitivity were only present upon co-expression of
N+C, but not N or C alone (Supplementary Fig. 10c–e).
Although lower than in the case of splice site A, the splicing was
still efficient, with over half of the N and C fragments being
converted into full-length receptors (Supplementary Fig. 10d). In
contrast to splice site A, co-expression of the N and splicing-
deficient C (S76A) constructs resulted in small ATP-gated
currents in response to high concentrations of ATP ( > 1 mM)
after long incubation times (>48 h). Of note, the prevention of
splicing favors side reactions, which will result in the accumula-
tion of cleavage products. It is thus possible that the non-covalent
assembly of the N and C cleavage products results in a receptor
population with impaired function, as evident from the drastically
reduced ATP sensitivity we observed (Supplementary Fig. 10e).
However, this result likely overstates the likelihood of cleavage
products occurring compared to when splicing-competent split
inteins are used. Overall, these data confirm that splicing can be
achieved within an extracellular domain of a membrane receptor.
In order to insert a peptide fragment into the extracellular
domain of P2X2 using tPTS, we used an analogous approach to
that described for Nav1.5 and GFP to generate three constructs:
(1) an N-terminal construct (N) corresponding to amino acids
1–53 of P2X2 fused to IntN of CfaDnaE; (2) a C-terminal
construct (C) containing a faux transmembrane domain linked to
IntC of SspDnaBM86 and amino acids 76–472 of P2X2; and (3) a
peptide X fragment (termed XP2X2REC) containing amino acids 54
to 75 of P2X2 flanked N- and C-terminally by IntC of CfaDnaE
and IntN of SspDnaBM86, respectively (Fig. 6a). To optimize
splicing efficiency, we additionally tested a C-terminal construct
with a cleavable faux transmembrane domain, which comprised
an IgK N-term signal sequence and a signal peptidase cleavage
site inserted between the faux transmembrane segment and IntC
of SspDnaBM86. The resultant current amplitudes confirmed
superior performance compared to the non-cleavable faux
domain (Supplementary Fig. 11), therefore further experiments
proceeded with this optimized C-terminal construct. Following
expression in Xenopus laevis oocytes, splicing of full-length, ATP-
gated receptors was only apparent when all three fragments (N, C,
and XP2X2REC) were present, and represented an estimated 7% of
the total products/reactants detected by immunoblotting (Fig. 6b,
c). Importantly, introduction of the S76A mutation at the +1
extein position of the C construct did not result in detectable
currents. Further, introduction of the K71Q mutation-bearing
peptide XP2X2REC into the spliced receptors shifted the ATP
concentration-response curve to the right to a similar degree as
the conventional K71Q mutant (Fig. 6d). Altogether, these data
demonstrate successful and splicing-dependent assembly of
functional P2X2 receptors upon co-expression of N, C, and
XP2X2REC constructs.
Finally, to test whether the position of the charge at K71 is
crucial for ATP recognition, we synthesized peptide XP2X2SYN
variants containing lysine and ncAA lysine derivatives (homo-
lysine, hLys, and ornithine, Orn) at position 71 (Fig. 6e), which
differed only in the length of their side chains. Following
recombinant expression of N and C in Xenopus laevis oocytes and
injection of synthetic peptide, successful splicing was confirmed
by functional responses to ATP application (Supplementary Fig.
IntC-A
IntN-B
IntN-A
IntC-B
N-GFP
Pept XGFPSYN
C-GFP Spliced-GFP
b
N+Csqueezed C+XsqueezedN+Xsqueezed
N+X+CsqueezedGFPtransfected
a
Fig. 5 Insertion of synthetic peptides into GFP. a Schematic of strategy
applied to reconstitute GFP from recombinantly expressed N-/C-terminal
fragments and a synthetic peptide XGFPSYN in HEK293 cells. b Overlay of
bright-field and fluorescence images taken of HEK293 cells transfected with
only WT GFP, or N and C fragments and squeezed in the presence or
absence of peptide XGFPSYN. Scale bars: 50 µm.
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12 and Fig. 6f). The ATP sensitivity of these responses
demonstrated that the Lys-containing peptide XP2X2SYN variant
generated WT-like responses, whereas those containing hLys and
Orn generated responses similar to those obtained with the
conventional K71Q mutant (Fig. 6f). We thus conclude that
efficient recognition of ATP by P2X2Rs is highly dependent on
the precise position of the charge at K71. However, ATP-
generated currents were markedly smaller (<5%) than those
recorded from full-length protein (WT) or from the spliced
product generated by co-expression of XP2X2REC with N and C,
even after attempts to increase the concentration of peptide
XP2X2SYN inserted into oocytes using multiple injections (see
Methods). Additionally, functional currents took a longer time to
manifest (3–5 days after peptide XP2X2SYN injection, compared to
1 day after WT and 3 days after N+ C+ XP2X2REC RNA
injection), indicating slow formation of the fully spliced product.
This low splicing efficiency was also evident from our inability to
use immunoblotting to detect bands corresponding to full-length
P2X2R. Application of the tPTS approach to incorporate hLys
and Orn at position 69 (replacing a different lysine residue
involved in ATP recognition) resulted in currents not distin-
guishable from background (Supplementary Fig. 12). This
suggested that the modification resulted in an even larger right-
shift in the ATP concentration-response curve, which cannot be
accurately determined. However, despite this low overall splicing
efficiency, we were able to use conventional PTS to reconstitute
functional P2X2Rs from N- and C-terminal fragments expressed
in HEK cells using only a single (CfaDnaE) split intein
(Supplementary Fig. 13), demonstrating that splicing within
extracellular domains is feasible in both Xenopus laevis oocytes
and mammalian cells.
Discussion
We have demonstrated that tPTS can be employed to introduce
single or multiple chemical modifications into soluble and
membrane proteins in live cells. This includes combinations of
ncAAs, PTMs or PTM mimics that cannot currently be incor-
porated into live cells using available methods. A key advantage of
the tPTS approach in live cells is that the refolding step typically
required with in vitro applications can be bypassed. This means
the approach can be used for larger, more complex proteins,
including those residing in the membrane. Additionally, the
approach does not rely on the ribosomal machinery and thus
delivers a homogenous protein population by avoiding the
potential for non-specific incorporation, which can affect protein
manipulation using non-sense suppression approaches32–36.
While tPTS offers unique ways to manipulate proteins, several
aspects require careful consideration for its applications in a
broader context. First, the splicing efficiency in tPTS is sequence-
a
c
e
d
f
50 -
60 -
160 -
110 -
80 -
AB: Anti-P2X2 (C-term)
WT
C
WT N+
C+
X 
RE
C
N+
C 
C+
X 
RE
C
N+
X 
RE
C
log [ATP]
–6 –5 –4 –3 –2 –1
N
or
m
al
iz
ed
 c
ur
re
nt
 (%
)
No
rm
al
ize
d 
cu
rre
nt
 (%
)
0
20
40
60
80
100
WT
[WT]REC
K71Q
[K71Q]REC
log [ATP]
–6 –5 –4 –3 –2 –1
0
20
40
60
80
100
[WT]SYN
[K71Orn]SYN
[K71hLys]SYN
N
-T
M
D
C-
TM
D
ER
P2X trimer
C
N
Nx
Fa
ux
 T
M
D
N
-T
M
D
N
C-
TM
D
CNx
Fa
ux
 T
M
D
Pept XP2X2REC
IntC-A
IntC-A
IntN-A
IntN-B
IntN-B
IntC-B
2
1
Pept XP2X2SYN
ATP
WT
5 µA 5 s
ATP ATP ATP ATP
1 µ A
5 s
N+XP2X2REC N+C+XP2X2RECN+C C+X P2X2RECb
N
H
O
NH3
N
H
O
NH3
N
H
O
NH3
K71
Orn71 hLys71
kDa 
Fig. 6 Insertion of recombinant and synthetic peptides into the P2X2R
extracellular domain. a Schematic presentation of the strategy to
reconstruct full-length P2X2Rs from recombinantly expressed N-/C-
terminal fragments (N and C) and a recombinant (strategy 1, Pept
XP2X2REC) or synthetic peptide (strategy 2, Pept XP2X2SYN) into the P2X2R
extracellular domain in Xenopus laevis oocytes. Note that a faux
transmembrane helix (faux TMD) was engineered into the C-terminal
fragment to maintain its native membrane topology (see also
Supplementary Fig. 9). Inteins A (CfaDnaE) and B (SspDnaBM86) indicated
by square and round symbols, respectively. Peptide X was designed to
include a C-terminal ER-targeting KDEL signal sequence, which is excised
during the splicing process. However, we cannot exclude the possibility that
splicing takes place at a different subcellular location than depicted here.
b Representative current traces obtained by application of 30 µM ATP,
verifying functional expression only when all three components were
recombinantly co-expressed (strategy 1 in a). c Immunoblot of surface-
purified proteins. Black arrows on the right indicate band positions of the
respective constructs (actual MW of constructs: WT, 53 kDa; C-construct,
97 kDa). Red arrow indicates the band of the spliced full-length receptor.
d ATP concentration-response curves (CRCs) for P2X2 WT (black) and
K71Q (red) reconstituted from the three co-expressed constructs. Dashed
lines represent the CRCs for the respective full-length proteins. e Structures
of inserted side chains at position 71 (Lys, Orn, hLys) incorporated via
synthetic peptide X (strategy 2 in a). f ATP CRCs indicate successful
incorporation of synthetic WT peptide XP2X2SYN (black) with wild-type like
ATP sensitivity, while synthetic peptides with Orn (pink) or hLys (blue)
resulted in a decrease in ATP sensitivity. Dashed lines indicate ATP CRCs
for spliced P2X2R WT (gray) or K71Q (purple) obtained with peptide
XP2X2REC. Values in d and f are displayed as mean+ /– SD; WT, n= 5;
[WT]REC, n= 8; K71Q, n= 7; [K71Q]REC, n= 9; [WT]SYN, n= 7; [K71Orn]
SYN, n= 9; [K71hLys]SYN, n= 5). Source data are provided as a Source
data file.
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dependent. In cases where the native sequence does not contain
residues required for splicing, mutations may need to be intro-
duced at the intended splice sites to fulfill the extein requirements
for successful splicing (i.e., the need for a Cys or Ser at the +1
extein position of the extein, see Fig. 1). Moreover, the protein
fragment to be modified needs to be within the length limit of
what is synthetically feasible. We also expect for example trans-
membrane sections of a protein to be less amenable to this
method, as they are challenging to synthesize and insert post-
translationally. Second, we note that numerous other split
inteins35 with different extein requirements could alternatively be
used for this approach and could potentially, depending on the
context, yield higher splicing efficiency. Here, we chose the split
inteins CfaDnaE and SspDnaBM86, as they have been well-
characterized with fast kinetics and engineered to have increased
tolerance to non-native extein sequences10,11. Importantly,
SspDnaBM86 can be split asymetrically with the IntN segment
only comprising 11 amino acids, making it an ideal split-intein B
in this approach (Fig. 1). Finally, the means of introducing the
synthetic peptide X needs to be optimized depending on the cell
type in question. While synthetic peptides can be injected directly
into Xenopus laevis oocytes, our approach requires potentially
more challenging delivery techniques, such as cell squeezing,
electroporation or the use of cell-penetrating peptides when
implemented in mammalian cells.
Unsurprisingly, for all the proteins tested here, we note that the
amount of fully spliced products generated using tPTS is gen-
erally lower, and their formation can take longer than when
expressing full-length WT proteins. Factors such as molecular
crowding or unfavorable spatial arrangements of protein frag-
ments in the cell could contribute to these issues. Furthermore, it
cannot be excluded that the recombinantly expressed protein
fragments display different stabilities toward the proteasome or
are differentially trafficked, resulting in unequal fragment ratios,
and thus potentially suboptimal conditions for splicing to occur.
The length, proteolytic stability, and solubility of synthetic pep-
tides, along with requirements for native-like flanking extein
sequences, can also affect splicing efficiency and reaction rates36.
Additionally, the amount of synthetic peptide that can be deliv-
ered into a cell is typically limited by the viability of the cell in
response to delivery of the peptide and peptide concentration.
Lastly, factors that contribute to optimal splicing conditions, such
as pH or redox potential, which are controllable in vitro, are
virtually impossible to manipulate in a live cell. Indeed, it is
possible that the lower splicing efficiency we observed when using
tPTS to modify the extracellular domain of the P2X2 receptor was
due to unfavorable redox conditions in the endoplasmic reticu-
lum and/or the low abundance of synthetic peptide in this sub-
cellular compartment (or others that the splicing could take
place in).
Nevertheless, it is important to appreciate that low protein
yields are also not uncommon with ribosome-based approaches
to genetically engineer proteins. This is particularly true for
complex proteins expressed in eukaryotic cells. In fact, many
groups have repeatedly observed yields of 10% or less with ncAA
incorporation into transporters37, ion channels38–40, and G
protein-coupled receptors41,42. Although the generally low yields
observed with tPTS likely restrict the approach to applications
that do not require large amounts of protein, at least some of the
above limitations can be addressed by engineering more pro-
miscuous and efficient split inteins10–12,43 or by adding affinity
tags to promote split intein interactions18. Such improvements
would allow the approach to be applied to a broader complement
of target proteins.
The ability to apply this approach in eukaryotic cells has
enabled us to use highly sensitive electrophysiology and imaging
techniques to determine the presence and functionality of fully
spliced products. tPTS will thus permit synthetic peptide inser-
tion into different proteins, in particular those that are amenable
to highly sensitive methods to study function or localization.
Beyond the introduction of PTMs, PTM mimics, and ncAAs, the
approach can be used to insert virtually any chemical modifica-
tion into a target protein, including backbone modifications,
chemical handles, fluorescent or spectroscopic labels, and com-
binations thereof. This constitutes an important advantage over
existing methodologies. Specifically, we anticipate that the
approach will overcome some of the drawbacks associated with
conventional genetic engineering in eukaryotic cells (non-specific
incorporation, premature termination, dependence on ribosomal
promiscuity37,44) and semi-synthetic approaches that require
protein refolding7. It will thus increase the number and type of
functionalities that can be incorporated into proteins that prove
amenable to tPTS.
Methods
Molecular biology. Plasmid DNAs were purchased from GeneArt (Thermo Fisher
scientific), General biosystems Inc. or Twist Bioscience. All gene constructs were
sub-cloned into either the pUNIV or pcDNA3.1+ backbone. pUNIV backbone was
a gift from Cynthia Czajkowski (Addgene plasmid # 24705; http://n2t.net/
addgene:24705; RRID:Addgene_24705). Conventional site-directed mutagenesis
was performed using standard PCR. Primer sequences are listed in Supplementary
Table 2. Complementary RNA (cRNA) for oocyte microinjection was transcribed
from respective linearized cDNA using the Ambion mMESSAGE mMACHINE T7
Transcription Kit (Thermo Fisher Scientific).
Peptide synthesis. Peptides for GFP splicing were sourced from Proteogenix,
France. Peptides for Nav1.5 and P2X2R splicing were synthesized by solid-phase
peptide synthesis (details in Supplementary material). Peptide X variants were
synthesized as three shorter fragments and assembled in a one-pot native chemical
ligation procedure, as briefly outlined below. The split intein-mediated recon-
stitution of proteins developed here required the synthesis of a small collection of
peptides between 69 and 77 amino acids in length. Conveniently, all peptide X
variants needed for our work share identical IntC-A (35 amino acids) and IntN-B
(11 amino acids) sequences, which flank the sequence corresponding to the protein
of interest (POI). In order to reduce the synthesis demands, we took advantage of
the sequences of IntC and IntN (i.e., Cys residues at +1 position in the exteins) by
adopting a “one-pot” chemical ligation strategy of three parts (IntC-A, POI seg-
ment and IntN-B), with the sequence from the POI being the only variable one. For
this purpose, a C-to-N-directed ligation strategy based on Thz masking of
cysteine45 was implemented for the assembly of the peptide X variants (Supple-
mentary Fig. 2). For the assembly of peptide X variants containing a thio-acetylated
lysine, a different ligation strategy (N-to-C directed) was adopted (Supplementary
Fig. 2) in order to avoid the Thz-cysteine unmasking step (acidic pH at 37 °C) of
the C-to-N-directed ligation. Indeed, our collaborators experienced partial con-
version of similar thioamide-containing peptides, likely into oxoamides, during
work-up and purification (Dr. Christian A. Olsen, personal communication).
Expression in Xenopus laevis oocytes. Stage V/VI oocytes were obtained from
ovaries of female Xenopus laevis frogs (anaesthetized in 0.3% tricaine, under license
2014-15-0201-00031, approved by the Danish Veterinary and Food Administra-
tion). cRNAs were injected into the oocytes (follicle layers enzymatically removed
by 0.5 mg/mL Type I collagenase39) and incubated at 18 °C in OR-3 solution (50%
Leibovitz’s medium, 1 mM L-Glutamine, 250 mg/L Gentamycin, 15 mM HEPES,
pH 7.6) for up to 7 days. For injection of synthetic peptides, lyophilized peptides
were dissolved in Milli-Q H2O to a concentration of 750 µM and 18 nL of solu-
bilized peptide was injected into cRNA pre-injected oocytes with the Nanoliter
2010 micromanipulator (World Precision Instruments). For NaV1.5 constructs,
synthetic peptides were injected 1 day after cRNAs were injected and recordings
performed 12–20 h after peptide injection. For P2X2 constructs, synthetic peptides
were injected consecutively on days 2, 3, and 4 following cRNA injection and
recordings performed on day 7.
Two-electrode voltage clamp (TEVC) recordings. Voltage or ATP-induced
currents were recorded with two microelectrodes using an OC-725C voltage clamp
amplifier (Warner Instruments). Oocytes were perfused in ND96 solution (in mM:
96 NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2/BaCl2, 5 HEPES, pH 7.4) during recordings.
Glass microelectrodes were backfilled with 3M KCl and microelectrodes with
resistances between 0.2 and 1MΩ were used. Oocytes were held at −100 mV (for
NaV1.5 constructs) or −40 mV (for P2X2 constructs). For NaV1.5, sodium currents
were induced by +5 mV voltage steps from −80 to +40 mV. Steady-state inacti-
vation was measured by delivering a 500 ms prepulse from −100 to −20 mV in +5
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mV voltage steps followed by a 25 ms test pulse of −20 mV. For P2X2 recordings,
ATP-induced currents were elicited through application of increasing concentra-
tions of ATP (dissolved in ND96, pH 7.4) supplied via an automated perfusion
system operated by a ValveBank™ module (AutoMate Scientific).
Immunoblots. Oocytes expressing full-length receptors or different combinations
of the split-intein receptor fragment fusion proteins were isolated 3–4 days after
RNA injection and washed twice with phosphate-buffered saline (PBS). Total cell
lysates were obtained by lysing the oocytes in Pierce™ IP lysis buffer with added
Halt protease inhibitor cocktail (Thermo Fisher Scientific). Surface proteins were
purified with the Pierce™ Cell Surface Protein Isolation Kit (Thermo Fisher Sci-
entific). Purified surface proteins or total cell lysates were run on a 4–12% BIS-TRIS
gel (for P2X2) or 3–8% Tris-acetate gel (for NaV1.5) and transferred to a poly-
vinylidene difluoride membrane. Membranes were incubated with rabbit poly-
clonal anti-NaV1.5 (#ASC-005, Alomone labs; 1:2000), anti-NaV1.5 (#ASC-013,
Alomone labs; 1:1500) or anti-P2X2 Antibody (#APR-003, Alomone labs; 1:2000)
and the bound primary antibodies were detected by a HRP-conjugated goat anti-
rabbit secondary antibody (W401B, Promega; 1:2000). Membranes were developed
and visualized using the Pierce™ ECL immunoblotting substrate (Thermo Fisher
Scientific).
Expression in HEK293 cells. HEK293 cells (American Type Culture Collection)
were grown in Dulbecco’s modified Eagle’s Medium (DMEM) (Gibco) supple-
mented with 10% fetal bovine serum (Gibco), 100 units/mL penicillin and 100 μg/
mL streptomycin (Gibco) and incubated at 37 °C with 5% of CO2. Confluent cells
growing in monolayers were washed with 10 mL PBS (in mM: 137 NaCl, 2.7 KCl,
4.3 Na2HPO4, 1.4 KH2PO4 (pH 7.3)), detached with trypsin-EDTA (Thermo Fisher
Scientific) and re-suspended in DMEM. The re-suspended cells were seeded onto
glass coverslips pre-treated with poly-L-Lysine in 35-mm dishes for patching or in
35-mm glass bottom dishes for imaging and incubated for 24 h, prior transfection.
The plated HEK293 cells were transfected using TransIT DNA transfection reagent
(Mirus) following the instructions supplied by the manufacturer and incubated
until use. For imaging of reconstituted GFP in HEK293 cells, DNA coding for three
GFP-split-intein fusion fragments (N, X, and C) was inserted into the pcDNA3.1+
vector by GeneArt (Thermo Fisher Scientific) and co-transfected in a 1:1:1 ratio
using a total of 3 µg DNA and incubated for 48 h. before imaging. In parallel, a
batch of cells was transfected with WT GFP as a positive control and in addition
five batches of cells were transfected with DNA coding for two fragments of the
GFP alone (N+ X, N+ C, X+ C) or combined with a non-splicing GFP fragment
(N+ X-Cys65Ala+C or N-X+C-Ser85Ala) as negative controls. To keep the
same amount of DNA for each combination pcDNA3.1+ empty vector was co-
transfected for the control experiments. For P2X2R patch-clamp recordings,
HEK293 cells were transfected in a 30 mm dish with 1.5 µg DNA of each construct,
respectively (N+ C, N+Cmut, N, C) and incubated for 2 days at 37 °C.
Imaging of reconstituted GFP. Imaging was performed using an inverted
microscope IX73 (Olympus) with 10x and 20x objectives mounted on a motorized
nosepiece (Olympus) controlled by a CMB U-HSCBM switch and connected to a
DCC1545-M camera (ThorLabs). GFP fluorescence was visualized using a LED
light source (CoolLed pE-100, 470 nm).
Peptide transfer by cell squeezing. Squeezing was performed using a chip with
constrictions of 6 µm in diameter and 10 µm in length (CellSqueeze 10-(6)x1,
SQZbiotech). In all microfluidic experiments, a cell density of 1.5 × 106 cells/mL in
Opti-MeM was squeezed through the chip at a pressure of 40 psi. Transduction was
conducted at 4 °C to block cargo uptake by endocytosis46. During squeezing, a
peptide concentration of 10–20 µM in the surrounding buffer was used. After
squeezing, cells were incubated for 5 min at 4 °C to reseal the plasma membrane.
Squeezed cells were washed with DMEM containing 10% FCS, seeded into 8-well
on cover glass II slides (Sarstedt) coated with fibronectin (5 µg/mL) in DMEM
containing 10% FCS, and cultured at 37 °C and 5% CO2. As a control for endo-
somal uptake, cells were incubated with 10 µM of peptide at room temperature
without microfluidic cell manipulation. Confocal imaging was performed 1, 2, 4, 8,
and 20 h after squeezing. Before imaging, cells were washed with PBS (Sigma-
Aldrich), fixed with 4% formaldehyde (Roth)/PBS for 20 min at 20 °C and quen-
ched by the addition 50 mM glycine in PBS (10 min, 20 °C).
Confocal laser-scanning microscopy. Imaging was performed using the confocal
laser-scanning (LSM) microscope LSM880 (Zeiss) with Plan-Apochromat 20×/1.4
Oil DIC objective. The following laser lines were used for excitation: 405 nm for
blue-shifted GFP and 488 nm for GFP. ImageJ47, Fiji48, and Zen 2.3 black (Carl
Zeiss Jena GmbH, Germany) were used for image analysis.
Patch-clamp electrophysiology. The cells were reseeded 1 to 4 h before the patch-
clamp experiments. Ionic currents were recorded with borosilicate patch pipettes
(2–5MΩ) filled with intracellular solution (in mM: 140 KCl, 5 MgCl2, 5 EGTA, 10
HEPES, pH 7.3) at −40 mV with the Axopatch 200B amplifier and the 1550A
digitizer (Molecular Devices). Lifted cells were perfused with extracellular solution
(in mM: 140 NaCl, 2.8 KCl, 2 CaCl2, 2 MgCl2, 10 HEPES, 10 Glucose, pH 7.3) and
activated with 1 mM ATP via a piezo-actuated perfusion tool.
Fluorescence-activated cell sorting (FACS). HEK293 cells were grown in Dul-
becco’s modified Eagle’s Medium (DMEM) (Gibco) supplemented with 10% Fetal
Bovine Serum (Biowest), and incubated at 37 °C with 5% of CO2. Four-hundred
thousand= cells were seeded in 6-well plates and incubated for 24 h, prior trans-
fection. DNA coding for three GFP-split-intein fusion fragments (N, X, and C) was
co-transfected in a 1:1:1 ratio using a total of 4.5 µg DNA. To keep the same
amount of DNA for each combination pcDNA3.1+ empty vector was co-
transfected for the N+ C and WT eGFP control experiments. Cells were trans-
fected using 6 µg PEI and incubated for circa 44 h. The cells were then detached
with trypsin-EDTA, spun down and re-suspended in PBS containing formaldehyde
37% (1:40) and DAPI 200 µM (1:200). The cell suspension was then passed through
a cell-strainer cap and analyzed with BD™ LSR II flow cytometer within 15 min.
Statistics and reproducibility. Electrophysiological data were recorded with
pClamp10 (Molecular Devices) and analyzed in Clampfit 10 (Molecular Devices).
Prism8 (Graphpad) and Sigmaplot 13.0 (SPSS) were used for statistical analysis.
Values and error bars in all graphs represent the mean and standard deviation from
at least five individual cells and two different batches, unless stated otherwise.
Statistical differences were determined using one-way ANOVA with a Tukey post-
hoc test, with p > 0.03 considered to be non-significant. Immunoblots and
microscope images shown are representative of experiments from at least two
batches of cells. FACS data was analyzed using FlowJo 10 (Becton Dickinson).
Chemical structures were made in ChemDraw16 (PerkinElmer) and figures were
prepared in Illustrator 2020 (Adobe).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data supporting the findings of this study are available in the manuscript and
supplementary files or are available from the corresponding author upon request. The
source data underlying Figs. 2c–e, 3c, e–f, 6c, d, f, and Supplementary Figs. 1c, 3a, 4c–e,
h–j, 5c, 8b, 9d–e, 10d–e, 11d are provided as a Source data file and are available on
Zenodo https://doi.org/10.5281/zenodo.3712821 [https://zenodo.org/record/3712821#.
Xp1pqP1KiUk] The pUNIV vector backbone was obtained from the Addgene repository
(Addgene plasmid # 24705; http://n2t.net/addgene:24705; RRID:Addgene_24705).
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